About Dravet Syndrome Stoke Therapeutics (Nasdaq ... not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be ...

Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Cronometer, a leader in nutrition and health tracking, is proud to announce the integration of Continuous Glucose Monitors (CGMs) with its innovative platform. This feature provides users with the ...

for treating Dravet syndrome. Following discussions with the FDA, the European Medicines Agency and Japan’s Pharmaceuticals and Medical Devices Agency, Stoke Therapeutics decided on the protocol ...

ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Epidiolex was first approved for rare epilepsy disorders Lennox-Gastaut syndrome and Dravet syndrome ... likely wouldn’t have been high on the list of possible suitors, and not too long ago ...

Janu Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine ...

Velsipity and Zeposia are both being offered to the NHS at a discount to their ex-VAT list prices of £11,000 ... ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...